Beyond Longevity

Beyond Longevity

Download on the App Store

Beyond Longevity episodes

  • AI, Ageing And The Question Of Trust with Dr Filippo Dall'Armellina

    Biology is undergoing one of the biggest transformations in its history. AI is helping researchers analyse enormous datasets, predict protein structures, identify drug targets, and accelerate scientific discovery in ways that would have been difficult to imagine just a few years ago. But AI is not replacing scientists. If anything, it is making human expertise, judgement, and scientific rigour more important than ever.

    In this conversation, we explore how the way science is done is changing. We discuss why so many promising discoveries never reach patients, why stronger collaboration between academia and industry matters, how breakthroughs such as AlphaFold are transforming biological research, and where AI is already delivering real-world results. We also ask some bigger questions: what can AI genuinely tell us about the human body, where are its limits, and are we sometimes confusing faster answers with deeper understanding?

    Dr Filippo Dall'Armellina is a biochemist with a PhD from the University of Liverpool, where his research combined wet lab science with computational methods, focusing on protein modelling and the application of artificial intelligence and deep learning to protein–lipid interactions for drug target discovery.

    Today, he advises pharmaceutical, biotechnology, and longevity companies on scientific and technical due diligence, clinical development strategy, and competitive landscape analysis, helping investors, founders, and leadership teams evaluate new technologies, therapeutic programmes, and emerging opportunities.

    His career spans academia, healthcare operations, and science communication. He has authored peer-reviewed publications, with his work featured in Science and discussed on the Science Podcast. He has contributed to studies on the physiological effects of suborbital spaceflight in collaboration with the European Space Agency (ESA), managed NHS COVID-19 vaccination programme operations across North West England, and produced Neuro Podcases, a clinical neuroscience podcast ranked among the world's top 5%, featuring researchers and clinicians discussing neuroscience, clinical trials, and translational medicine.

    Alongside his advisory work, Dr Dall'Armellina continues to collaborate with the University of Liverpool while supporting organisations working across biotechnology, pharmaceuticals, longevity, and human health.

    Connect with Dr. Dall'Armellina on LinkedIn 🔗 Latest Publication

    00:00 Welcome and Guest Intro

    02:08 Filippo Background Journey

    05:03 Skipping Masters to PhD

    08:33 Embracing Research Chaos

    12:39 Academia Industry Bridge

    19:46 Why Discoveries Fail

    23:44 AI in Structural Biology

    32:15 AlphaFold Explained

    36:58 Prediction vs Understanding

    41:42 AI Meets Longevity

    47:04 Next Five Years for AI

    49:28 AI Hype and Missteps

    53:07 Rapid Fire and Wrap Up

    56:21 Final Takeaways Outro

    58 min
  • Kyle Holbert on Heavy Metals, Missed Diagnoses and Making Longevity Medicine More Accessible

    Beyond Longevity interviews Kyle Holbert, COO and co-founder of Longevity Centres of America, about how unexplained fatigue, brain fog, depression, anxiety, joint pain and gut issues derailed his health despite a healthy lifestyle and years of searching for answers.

    After seeing multiple GPs and therapists who either dismissed his symptoms or could not identify a cause, Kyle discovered he had severely low testosterone. Treatment with HCG led to a rapid improvement in his mental health and highlighted some of the limitations of time-constrained, symptom-focused healthcare.

    When other symptoms persisted, he turned to biohacking and concierge medicine. A heavy metals provocation test later suggested chronic mercury toxicity, and a year of intensive chelation and IV-based treatment became a turning point in his recovery, ultimately leading him to leave the family construction business and move into longevity medicine.

    The episode explores potential sources of mercury exposure, why individuals can respond very differently to similar toxic burdens, scepticism around many at-home detox products, and the importance of testing and clinician-guided treatment plans. Daphna and Kyle also discuss affordability, access to care, and the foundational role of movement, clean water, whole foods and targeted supplementation.

    Website: https://www.thelcoa.com/longevity-unlocked-podcast/

    Podcast: @longevityunlockedpod (https://www.instagram.com/longevityunlockedpod/)

    Greenville, SC: @thelcgreenville (https://www.instagram.com/thelcgreenville/)

    West Palm Beach, FL: @thelcfl (https://www.instagram.com/thelcfl/)

    Dr K on Instagram: @theosteodoc

    00:00 Podcast Setup

    01:50 Kyle’s Early Life

    04:26 Health Decline Begins

    07:13 Dismissed by Doctors

    12:20 Biohacking Breakthrough

    15:40 Conference and Deeper Testing

    17:38 Mercury Diagnosis and Chelation

    19:38 Building Longevity Centres

    20:30 Detox Timeline and Protocols

    23:27 Sources of Heavy Metals

    26:50 Generational Toxic Buildup

    27:33 How Common Are Metals

    28:12 Why Symptoms Vary

    29:27 Detox Even If Fine

    31:14 Detox Hype vs Reality

    34:30 Making Care Affordable

    40:52 How to Vet Clinics

    43:40 Start With Basics

    45:15 Avoid Longevity Traps

    49:34 Supplements and Telehealth

    53:09 Rapid Fire and Wrap

    55:50 Final Takeaways

    58 min
  • The Sugar Language of Ageing - Glycans, Inflammation, and Your Immune Age with Nikolina Lauc

    In this episode of Beyond Longevity, Daphna speaks with Nikolina Lauc, CEO and co-founder of GlycanAge, about glycobiology, immune ageing, and the role of chronic inflammation in ageing.

    Nikolina explains why glycans, the complex sugar structures attached to our antibodies, may offer one of the clearest windows into the state of the immune system. The conversation explores “inflammaging”, the idea that chronic, low-grade inflammation may not simply be a consequence of ageing, but one of the forces actively driving it.

    They discuss why antibody glycans may capture biological risk earlier than routine markers such as CRP, including research suggesting that glycan-based changes can appear years before standard blood tests show anything is wrong. Nikolina also explains how glycan testing may help predict disease risk and mortality and why repeat testing can reveal whether lifestyle changes are having a measurable biological effect.

    Daphna and Nikolina also explore biological-age clocks, stress, high-performance lifestyles, exercise, pregnancy, menopause, and the strong influence of sex hormones, including HRT. The episode looks at why glycan testing is not yet part of routine clinical practice, the technical barriers involved, and the bigger question at the heart of preventive health: what should we do when we can see risk before disease appears?

    GlycanAge showed very high reproducibility both in the blinded sample experiment run by Jamie Haywood at Alden Scientific, and independently in collaboration with Mike Snyder’s group at Stanford [Stanford paper reference]. Epigenetic clocks showed significant day-to-day oscillations in epigenetic age measurements [daily oscillation paper reference], which becomes important when trying to measure relatively small intervention effects over time.

    We recently completed a UK Biobank study showing that the glycan markers we measure were more predictive of all-cause mortality than routine blood biochemistry alone; combining both further improved prediction performance (sharing the pre-print here).

    We also published a large study across 42 cohorts and ~20,000 individuals showing that GlycanAge predicts all-cause mortality independently of traditional risk factors including BMI, CRP, hypertension, smoking, LDL, diabetes, cardiovascular disease history, and kidney markers. Across cohorts, every additional GlycanAge year was associated with roughly a 5-10% increase in all-cause mortality risk (sharing the pre-print here).

    Another recent preprint evaluating epigenetic age clocks showed they do not substantially improve prediction of morbidity and mortality beyond information already captured through routine clinical blood biomarkers and standard risk factors [epigenetic clock preprint reference].

    Background and key references are below:

    GlycanAge intro

    GlycanAge is a clinically validated biomarker platform originating from the work of Professor Gordan Lauc. Over the past five years, we've translated his research into a scalable clinical biomarker.

    Today, GlycanAge is used in more than 2,000 private clinics worldwide and collaborates with leading academic and clinical partners including Mayo Clinic, Harvard Medical School, Northwestern Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, King Abdulaziz City for Science and Technology, Clinique La Prairie and many others, supporting both immune age tracking and disease-focused applications, particularly in cardiovascular and metabolic health.

    Key references below:

    Scientific Founder & Origins

    Professor Gordan Lauc is one of the pioneers of human glycomics and co-founded the Human Glycome Project (with Harvard’s Richard Cummings). He discovered GlycanAge as one of the first systemic measures of biological aging based on immune glycosylation.

    • Founder, Genos Research Institute
    • Professor of Biochemistry, University of Zagreb
    • Honorary Professor, King’s College London
    • Johns Hopkins Scholar
    • 800+ publications • 20,000+ citations • H-index 77

    A New Class of Biological Clock

    GlycanAge is the first inflammaging clock, measuring chronic low-grade inflammation through IgG glycosylation, independent of acute events.

    • First published in The Journal of Gerontology 2013
    • Validated in 350+ peer-reviewed papers across >300,000 human samples
    • Highest precision in the field: <1% analytical variation
    • Independently confirmed by Stanford (GeroScience 2024)

    Prediction of Morbidity & Mortality

    Glycan signatures predict multiple future clinical outcomes; I'm sharing a review (Biotechnology Advances 2023) linking IgG glycans to 72+ disease indications, where we see specific glycan shifts up to 10 years before symptoms onset or clinical diagnosis.

    Cardiovascular disease

    • Harvard-led studies showed up to 2× increased ASCVD risk, independent of LDL, CRP, BMI (Circulation Research 2024, Journal of Clinical Lipidology 2025)
    • In a Middle Eastern replication cohort, IgG N-glycans predicted a ~2× higher risk of premature myocardial infarction, independent of traditional risk factors (European Heart Journal 2025).
    • First biomarker demonstrating female-specific cardiovascular risk patterns (Diabetes Care 2022)

    Diabetes

    • Glycan changes predict transition from normoglycemia → pre-diabetes → T2D years in advance with AUC 0.895 (Cardiovascular Diabetology 2025)
    • In children with new-onset Type 1 diabetes, distinct IgG and plasma N-glycan changes enabled strong discrimination between cases and controls AUC ≈ 0.915 (Diabetologia 2022).

    Cross-Population Validation

    Beyond European cohorts: in a study of 27 populations across 14 countries, IgG glycosylation patterns tracked with age/sex and correlated with life expectancy and national health indices (HDI, SDG, MDG), demonstrating validity across genetically and environmentally diverse populations (Aging 2020).

    Interventions GlycanAge Responds To:

    • Caloric restriction & fasting (Nature Aging 2025, Frontiers 2022 + pre-publication on fasting)
    • Exercise (Glycoconjugate journal 2024)
    • Menopausal HRT & testosterone therapy (Aging 2020, GeroScience 2025, JCI Insight 2017)
    • Weight loss & GLP-1 therapy (Journal of Obesity 2021 + pre-publication on GLP-1 )
    • Therapeutic plasma exchange (Aging Cell 2025)

    00:00 Welcome to Beyond Longevity

    00:41 Meet Nicolina Loud

    02:33 Glycans Explained Simply

    05:02 Glycans Everywhere in Biology

    06:46 Inflammaging and Ageing Theory

    08:37 Why Glycans Beat Standard Markers

    12:10 From Lab Discovery to Company

    15:51 What Glycan Age Measures

    17:57 Does Biological Age Matter

    20:41 Inequality Stress and Ageing

    24:37 Athletes and High Performer Costs

    28:04 Which Ageing Clocks to Trust

    29:35 Variability and Real-World Example

    34:20 Epigenetic Clocks Mechanism Unknown

    35:03 Epigenetic Clock Limits

    36:36 Combining Clocks Wisely

    38:28 Longitudinal Testing Strategy

    39:44 Personalised Interventions

    42:14 Retesting Cadence

    44:17 Pregnancy Immune Reset

    45:53 Hormones and Glycan Age

    51:30 Why Not Routine Care

    54:45 Future of Prevention

    58:49 Rapid Fire Takeaways

    01:00:57 Young Plasma Frontier

    01:04:34 Closing Reflections

    1 hr 7 min
  • Beyond Supplements with Alan Graves on Funding Clinical Trials and Longevity Research

    Daphna sat down with Alan Graves, founder of DoNotAge, for an in-depth conversation about what it takes to make longevity science more credible, more collaborative and more accessible.

    After a serious health decline in his late twenties, Alan entered the longevity field after learning that ageing may be more malleable than he had once thought. He went on to build DoNotAge as a self-funded health research organisation, using consumer supplements to help fund ageing research, support external labs and emerging researchers, provide high-purity ingredients for independent studies, and translate complex science into language people can actually understand.

    The conversation covers why longevity science is still difficult to access, why the supplement industry has a credibility problem, and how marketing, underdosing and weak “science-backed” claims have made it hard for consumers to know what to trust.

    Alan also discusses the realities of clinical trials, why they are slow and expensive, and the studies DoNotAge is currently supporting or planning, including work around spermidine, NAD, Crohn’s disease, berberine and biological age clocks.

    In striving to make longevity easier and more practical, Alan has also introduced a one-a-day sachet designed to simplify adherence. They also explore his focus on sirtuin 6 activation, DoNotAge’s free London conference, and the wider aim of making longevity more affordable, practical and collaborative.

    DoNotAge.org is a health research organisation.

    You can learn more at https://routine.donotage.org

    00:00 Welcome and Guest Intro

    02:52 Alan’s Unlikely Origin Story

    04:34 From Self-Experiment to Do Not Age

    06:45 Funding Gap and New Model

    08:12 Democratising Longevity Science

    09:48 Research Company Not Supplements

    11:09 Why Clinical Trials Take Years

    12:50 How Do Not Age Is Structured

    15:09 Supporting Labs Worldwide

    18:01 Supplement Industry Credibility Crisis

    21:01 How Consumers Verify Claims

    22:42 Stepping Down as CEO

    25:11 Choosing Which Research to Fund

    26:45 Upcoming Trials and What’s Next

    28:10 Basics Before Supplements

    31:43 Testing and Biological Age

    33:24 The One-a-Day Sachet Idea

    36:03 Clinical Trials Pipeline

    36:55 Making Longevity Affordable

    39:58 Pricing Ethics and Dosage

    41:33 Hype vs Evidence in Longevity

    44:51 Who Needs Supplements When

    46:55 Free Unbiased Science Conference

    53:02 What Excites Him Next

    54:08 SIRT6 Activator Deep Dive

    58:30 Why Healthcare Won’t Adopt It

    01:01:44 Boxing, Balance, and Ageing Goals

    01:04:41 Rapid Fire and Wrap Up

    01:07:15 Host Takeaways and Conclusion

    1 hr 9 min
  • How Nutrition Can Impact Longevity and Healthspan. The Age Code with Dr David Cox

    In this episode of Beyond Longevity, Daphna speaks with Dr David Cox, a health journalist (BBC, The Guardian, The Telegraph, NBC News and others), who holds a PhD in neuroscience from the University of Cambridge and is the author of The Age Code, about how diet, ultra-processed foods and the modern food environment shape biological ageing.

    Dr David argues that the longevity conversation often focuses too heavily on future drug breakthroughs, supplements and biohacking, while overlooking lower-hanging fruit that could already have a meaningful impact on long-term health. He explains why reducing ultra-processed foods, increasing fibre intake and paying closer attention to micronutrients such as vitamin K may matter far more than many people realise.

    The conversation explores gut ageing and its relationship with immune ageing, possible drivers behind the rise in early-onset cancers, and practical lifestyle strategies that may support healthier ageing. These include slow cooking, eating more protein and calories earlier in the day, lowering dietary acid load through fruits, vegetables and herbs, and the role omega-3s may play in long-term health.

    Daphna and Dr David also discuss biological ageing tests, visceral fat, kidney health markers, the limitations of CGMs for the average person, exercise mimetics, affordability within longevity medicine, and whether governments should take a far more active role in tackling the everyday drivers of chronic disease and accelerated ageing.

    The Age Code: https://www.amazon.co.uk/dp/0008708878

    https://www.instagram.com/drdavidcoxhealth

    https://www.linkedin.com/in/dr-david-cox-6b219666

    00:00 Welcome and Guest Intro

    02:00 From PhD to Journalism

    03:17 Science Scepticism and Nuance

    05:22 Trust Crisis in Health

    06:44 Protein Hype vs Fibre

    07:40 Micronutrients Matter

    09:07 Inside The Age Code

    10:50 Early Onset Cancer Clues

    12:38 Gut Ageing Explained

    14:49 Ten Nutritional Stressors

    17:55 Ultra Processed Food Reality

    19:32 Personal Choice vs Policy

    23:33 Longevity Focus Misplaced

    25:00 Ageing Tests and Omega 3

    27:39 Advice for Any Budget

    29:48 Sauna Protocols

    31:04 Metabolomics Health Snapshots

    33:16 Testing Anxiety and Rule of Three

    35:41 His Own Biomarker Wake Up

    37:41 Best and Overrated Biomarkers

    41:25 Exercise Mimetic Drugs Debate

    48:05 Government and Ageing Strategy

    50:23 Kitchen Takeaways and Seaweed

    53:18 Rapid Fire Round

    56:08 Final Reflections and Outro

    58 min
  • Supplements, Science and the Longevity Marketing Machine

    Supplements promise a lot: mitochondrial support, better brain health, healthier gut function, anti-ageing benefits and more.

    But how much of that is real science, and how much is simply clever wording on a label?

    In this episode of Beyond Longevity, Dr Luke Bucci, PhD, Chief Scientific Officer at Juvenon, brings both a scientist’s eye and decades of experience in the supplement industry to one of the most confusing areas of longevity.

    Dr Luke explains the difference between a product being described as “science-backed” and one that is supported by meaningful human clinical evidence. He also discusses why the dose, form and standardisation of an ingredient matter, and why “fairy-dusting” fashionable ingredients into a formula can make a product sound far more proven than it really is.

    We talk about bioavailability, absorption, the gut microbiome, and why feeling stimulated is not the same as supporting mitochondrial health. Dr Luke also explains why creatine has moved beyond the gym, why blood flow and nitric oxide matter as we age, and how nutrients such as magnesium, vitamin D3, omega-3s, polyphenols and CoQ10 fit into a more thoughtful approach to supplementation.

    This is a practical and refreshingly honest conversation about how to read beyond the label, ask better questions, and think more clearly about what supplements can, and cannot, do.

    Links:

    Instagram: https://www.instagram.com/juvenonwellness

    Facebook: https://www.facebook.com/Juvenon/

    Website: https://juvenon.com/

    00:00 Welcome and Guest Intro

    01:53 Dr Bucci Origin Story

    03:26 Science vs Marketing Today

    04:44 Science Backed vs Clinical

    09:14 Fairy Dusting Exposed

    11:05 Bioavailability Reality Check

    14:15 Standardisation and Sourcing

    22:03 Gut Microbiome Benefits

    24:30 Testing and Trial Periods

    27:33 Longevity Trend Explained

    30:35 Mitochondria 101

    34:14 Stimulants vs Real Energy

    40:47 Stimulant Band Aid Trap

    41:51 Creatine Beyond The Gym

    45:08 Creatine Dosing And Safety

    47:11 Creatine For Brain Ageing

    50:53 Why Blood Flow Declines

    53:42 Nitric Oxide Basics

    57:44 Arginine Silicate Explained

    01:04:45 Polyphenols And Nitrates

    01:06:53 My Essential Supplements

    01:11:36 Rapid Fire Wisdom

    01:13:49 Episode Takeaways

    1 hr 17 min
  • Longevity Needs a Scientific Sanity Check: Dr Herna de Wit on Evidence, IP and South Africa’s Role in the Future of Healthspan

    This week on Beyond Longevity, I am joined by Dr Herna de Wit, CEO and Founder of Omnisci Consulting, with a PhD in Biochemistry and an LLB in Law.

    Dr Herna brings a very unusual and valuable combination to the longevity conversation: deep scientific training, legal expertise and hands-on experience advising companies in the health, biotech and longevity space.

    Longevity is full of exciting science, but it is also a field where marketing can move faster than evidence. In this episode, we ask a simple but important question: how do we separate what is genuinely credible from what merely sounds convincing?

    Dr Herna shares her five-point “scientific sanity check” for evaluating longevity products, supplements and protocols. We discuss why human RCT data matters more than animal or cell studies, why dosage and bioavailability are often overlooked, what biological age clocks can and cannot tell us, and why safety, third-party testing, and regulatory discipline are essential in a fast-moving market.

    We also look at longevity from the perspective of investors and company builders. What are the red flags? What makes a claim scientifically weak? And why does defensible intellectual property matter far beyond simply having a patent?

    Dr Herna explains how companies can think more intelligently about protectability, including through delivery systems, synergistic formulations, data, know-how and clearer scientific positioning.

    The conversation then turns to South Africa, a market that many listeners may not immediately associate with longevity, but one that raises fascinating questions. We discuss medical tourism, scientific talent, regulatory realities, affordability and whether South Africa could carve out a distinctive role in the global healthspan conversation.

    Finally, we speak about one of the most important tensions in longevity: if the science advances, who actually gets access? Is longevity already becoming another layer of privilege, or can the field develop in a way that is more credible, more inclusive and more useful?

    This is a conversation about evidence, accountability and the future of a field that urgently needs both excitement and discipline.

    Links:

    https://www.linkedin.com/in/herna-de-wit-phd-llb/

    https://linktr.ee/drherna.omnisci

    00:00 Show Intro and Guest

    02:41 Dr Herna’s Unusual Path

    04:29 What She Does Today

    06:13 Five Point Science Audit

    11:17 Investor Red Flags

    15:31 IP Beyond Patents

    20:12 Open Science vs Profit

    24:35 Founder IP Strategy

    32:54 Global Longevity Hotspots

    33:42 South Africa Opportunity

    36:33 Access and Inequality

    43:12 Regulation and Innovation

    46:20 How to Work With Dr Herna

    50:02 Rapid Fire Questions

    52:20 Final Takeaways Outro

    55 min
  • Dr Filippo Ongaro: Space as an Accelerated Ageing Model, Health Span and the Behaviour Gap in Longevity

    On Beyond Longevity, Dr Filippo Ongaro, medical doctor, entrepreneur, and strategic advisor, shares how nearly eight years working with astronauts at the European Space Agency shaped the way he thinks about ageing.

    In space, the body can lose muscle, bone and resilience at a frightening speed. Stress, sleep disruption, nutrition, movement and circadian misalignment are not lifestyle details. They become central medical issues. For Dr Filippo, space became a kind of accelerated ageing model, showing in fast-forward what happens when the systems that keep us strong begin to break down, and why exercise and nutrition are such powerful countermeasures.

    After leaving ESA, Dr Filippo opened one of Italy’s early anti-ageing and functional medicine centres. But over time, he came to believe that the biggest obstacle in longevity is not simply knowledge, testing, or more biomarkers. It is the behaviour gap. People often know what they should be doing. The harder question is why they do not follow through.

    Together with his wife Sonya, he shifted from one-to-one clinical work into education, coaching, professional training and strategic advisory, with a focus on making longevity more accessible, affordable and practical, including through pharmacy-based pathways.

    In this conversation, he argues that longevity should focus on healthspan, avoid overpromising, build trust, start earlier with younger people, and move beyond fear of death towards purpose, identity and the joy of life

    links: www.metodo-ongaro.com

    https://www.linkedin.com/in/dr-filippo-ongaro/

    Dr. Filippo Ongaro

    00:00 Welcome and Guest Intro

    02:53 From ESA to Longevity

    05:07 Space as Accelerated Ageing

    07:40 Countermeasures and Behaviour Gap

    09:53 Mindset Over Biohacking

    14:24 Mission Drives Discipline

    17:22 Delayed Gratification Science

    20:37 Building Anti-Ageing Practice

    22:11 Why People Don't Follow Through

    24:31 Who Wanted Anti-Ageing Help

    28:16 Pivot to Education at Scale

    31:53 Training Health Professionals

    32:24 Scaling Impact Through Partners

    33:27 Broadening the Audience

    34:36 Affordable Longevity Access

    37:11 Institutions and Mass Market

    40:14 Business Advice for Clinicians

    43:26 Hype, Trust, and PR

    45:07 Fear Versus Joy of Life

    47:16 Identity Driven Change

    53:24 Future of Longevity Market

    56:00 Healthspan Over Lifespan

    57:58 Rapid Fire and Wrap Up

    01:00:18 Final Episode Takeaways

    1 hr 4 min
  • Building a Longevity Nation. Reimagining the Second Half of Life with Michael Clinton

    Michael A. Clinton, former President of Hearst Magazines.

    Michael spent four decades at the top of the publishing world, including as President and Publishing Director of Hearst Magazines, before turning his attention to one of the biggest questions of our time. If many of us are likely to live longer than previous generations, how do we make the second half of life not just longer, but more intentional, productive and meaningful?

    In this episode of Beyond Longevity, Michael discusses the ideas behind his book ROAR and his framework for rethinking later life. ROAR stands for Reimagine, Own your numbers, Action plan and Relationships, and it became the foundation for Roar Forward, his B2B platform advising organisations on the fast-changing 50-plus consumer.

    The conversation explores why Michael believes we need to shift the language from “ageing” to “longevity”, how culture and business are slowly beginning to respond, and why institutions, employers and policymakers still have a long way to go.

    Michael also previews ideas from his new book, Longevity Nation, which looks at the people, companies and innovations reshaping what longer lives could mean. He raises important concerns about inequality, access and the growing number of products making claims that are not always backed by evidence.

    This is also a very personal conversation. Michael reflects on his working-class roots in Pittsburgh, the moment that changed how he thought about identity and reinvention, and why the longest chapter of life may be the one most people have planned for the least.

    The episode also touches on the economic power of the $8.3 trillion 50-plus consumer, why this market is still widely misunderstood, and the one longevity habit Michael believes anyone can begin with, regardless of income.

    Links:

    Longevity Nation

    ROAR forward

    LinkedIn

    00:00 Welcome and Guest Intro

    02:19 Early Life and First Memory

    03:17 Ambition and Upbringing

    05:12 Finding His Career Path

    06:29 Hearst Lessons on Identity

    09:22 ROAR Framework Explained

    13:29 Longevity Economy for Business

    16:19 Language and Pro Age Messaging

    18:43 Brands and Countries Adapting

    21:55 Fear and Reinvention Mindset

    22:59 Purposeful Second Act

    23:38 Reimagineer Stories

    24:37 Why Longevity Nation

    27:33 Inequality and Access

    30:13 America and 100 Year Life

    33:18 Policy Gaps to Fix

    35:53 Hope Worries Takeaway

    40:16 Rapid Fire Round

    42:42 Longevity Habits and Myths

    45:05 Closing Reflections

    47 min
  • The Promise and Problem of Longevity Testing; Prevention, Access and the Inequality in the field with Niko Hems

    What does good prevention actually look like, and is the longevity industry helping people live better, or simply making health feel more complicated?

    In this episode of Beyond Longevity, Daphna speaks with Niko Hems, Operations Lead at YEARS, a longevity clinic in Berlin, Germany.

    Niko brings a rare perspective to the conversation. He works inside the longevity field, but he is not afraid to challenge it. He believes deeply in prevention, yet he is sharply aware of where the industry can go wrong, from over-testing and over-promising to fringe science and the uncomfortable gap between those who can afford cutting-edge healthcare and those who are still struggling to access the basics.

    His own story makes this especially interesting. At 13, Niko became fascinated by nutrition and fitness while trying to gain weight and feel better in his body. Years later, after completing a Master’s in Longevity Sciences and working inside one of Germany’s leading longevity clinics, he put himself through the kinds of tests many people now associate with the future of health, including genome sequencing, microbiome analysis and more than 200 biomarkers.

    The result was not quite what he expected. Instead of clarity, much of it created anxiety. Instead of answers, it raised a harder question: when does prevention become too much?

    This is a refreshingly honest conversation about the promises and problems of modern longevity, the tests that help versus the ones that confuse, the basics that still matter most, and what a more credible, useful and accessible version of prevention could look like.

    Niko Hems Head of Growth at YEARS.

    Host of Return on Health podcast.

    Links:

    https://nikohems.de

    https://www.linkedin.com/in/niko-hems/

    https://returnonhealth.de/

    00:00 Podcast intro and themes

    01:52 Nico’s path into longevity

    03:37 Defining longevity and healthspan

    04:47 Peakspan explained

    06:26 Basics that move the needle

    08:32 When testing becomes anxiety

    10:07 Inside the Years clinic model

    14:26 Cost access and inequality

    15:58 Who buys high-end programs

    17:55 What 16K actually includes

    20:43 Why behaviour change is hard

    24:07 Are we really getting healthier

    26:04 Lifespan hype vs healthspan focus

    28:25 Prevention Over Testing

    29:23 Affordable Core Diagnostics

    30:50 Why Healthcare Lags

    32:58 Fixing Incentives

    37:37 Longevity Branding Problem

    41:09 Basics That Move Needle

    43:28 Free High Impact Habits

    46:22 AI And Longevity Future

    52:04 Rapid Fire Wrap Up

    53:42 Final Takeaways

    56 min

About Beyond Longevity

From the publisher's feed

Beyond Longevity explores the science, medicine, technology, business and policy shaping longer, healthier lives. Host Daphna Stern speaks with leading researchers, clinicians, founders and experts…